CLP1R, GCGR, and GIPR are crucial drug targets for treating metabolic diseases.
CLP1R is involved in regulating insulin secretion; GCGR plays a key role in glucose homeostasis and is a major target for diabetes drug development; GIPR mediates incretin effects and influences energy metabolism.
Our company offers high-quality drug-target cells for these receptors, supporting high-throughput screening and activity validation to accelerate drug discovery for metabolic disorders.
Figure 1. Dose Response of Agonists in GLP1R&CTR/RAMP3 Dual Reporter Cell(C49)
The CRE-luciferase reporter assay shows distinct agonist potency, confirming both receptors are functionally active. This dual-receptor cell model is suitable for pharmacological evaluation and multi-target agonist screening.
Figure 2. HTRF cAMP Assay with GLP1R&CTR/RAMP3 Dual Reporter Cell(C49)
Multiple agonists exhibited distinct dose-dependent responses with different EC50 values. The data verifies both receptors are functionally active, suitable for pharmacological profiling and multi-target agonist screening.
